Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
16 pending office actions • 8 clients • 14 examiners • 11 art units • 1 of 16 (6%) have an AI response strategy ready
MEDLEN & CARROLL, LLP has 2395 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 73.05 percent. Successful applications average 4.36 office actions per allowance.
There are 15 pending office actions currently active. The 4.36 average office actions per allowance indicates a relatively high number of interactions with the patent office for the 73.05 percent of cases that reach allowance. This data provides a clear view of the firm's long-term performance and current workload across its 2395 career applications in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 3 (19%) |
| §102 only | 1 (6%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 6 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 2 | 50.8% | +50.2% |
| KONOPKA, CATHERINE ANNE | 2 | 58.1% | +65.0% |
| BOWMAN, ANDREW J | 1 | 65.9% | +13.2% |
| NICONOVICH, ALEXANDER R | 1 | 72.8% | +21.9% |
| WASHINGTON, BRITNEY NICOLE | 1 | 83.1% | +13.2% |
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
| WARD, AARON DUREL | 1 | — | — |
| SINES, BRIAN J | 1 | 80.1% | +5.2% |
| GHERBI, SUZETTE JAIME J | 1 | 85.0% | +8.8% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18520821 | CONTROLLING PRESSURE | SINES, BRIAN J | 55d |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639428 | DISCERNING BRAIN CANCER TYPE | MACFARLANE, STACEY NEE | 11d overdue |
| 18591819 | HOST-BIOME INTERACTIONS | AFREMOVA, VERA | 4d overdue |
| 18027834 | CONTINUOUS INFRARED SPECTROSCOPY SYSTEM AND METHOD | KIDWELL, KAITLYN ELIZABETH | 2d overdue |
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | NICONOVICH, ALEXANDER R | — |
| 18577623 | MODULAR PRIME EDITING SYSTEMS FOR GENOME ENGINEERING | WARD, AARON DUREL | — |
| 18497519 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITUS | GHERBI, SUZETTE JAIME J | — |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | KONOPKA, CATHERINE ANNE | — |
| 17608684 | CONVERSION OF CARBONATE INTO SYNGAS OR C2+ PRODUCTS IN ELECTROLYSIS CELL | PARENT, ALEXANDER RENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18980456 | Targeted CRISPR Delivery Platforms | LEONARD, ARTHUR S | 50d overdue |
| 17921027 | IMPROVED CAS 12A/NLS MEDIATED THERAPEUTIC GENE EDITING PLATFORMS | KONOPKA, CATHERINE ANNE | 16d overdue |
| 18591819 | HOST-BIOME INTERACTIONS | AFREMOVA, VERA | 4d overdue |
| 18810072 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS | BOWMAN, ANDREW J | 72d |
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | NICONOVICH, ALEXANDER R | — |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
| 18612111 | Targeted CRISPR Delivery Platforms | LEONARD, ARTHUR S | — |
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | PUTTLITZ, KARL J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| UNIVERSITY OF MASSACHUSETTS | 5 |
| EMULATE, Inc. | 3 |
| Lyra Therapeutics | 2 |
| DXCOVER LIMITED | 2 |
| Claymates LLC | 1 |
| AmberGen, Inc. | 1 |
| THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO | 1 |
| Signablok, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1631 | 1 |
| 1717 | 1 |
| 3711 | 1 |
| 1653 | 1 |
| 1796 | 1 |
| 3774 | 1 |
| 2877 | 1 |
| 1675 | 1 |
| 1700 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18980456 | Targeted CRISPR Delivery Platforms | UNIVERSITY OF MASSACHUSETTS | LEONARD, ARTHUR S | 1631 | §112DP | Non-Final OA | 50d overdue | Pending | Dec 13, 2024 |
| 18810072 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS | Lyra Therapeutics, Inc. | BOWMAN, ANDREW J | 1717 | §103 | Non-Final OA | 72d | Pending | Aug 20, 2024 |
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | Claymates LLC | NICONOVICH, ALEXANDER R | 3711 | §102§103§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | Emulate, Inc. | WASHINGTON, BRITNEY NICOLE | §102 | Non-Final OA | — | Pending | May 09, 2024 | |
| 18612111 | Targeted CRISPR Delivery Platforms | UNIVERSITY OF MASSACHUSETTS | LEONARD, ARTHUR S | §103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 | |
| 18591819 | HOST-BIOME INTERACTIONS | Emulate, Inc. | AFREMOVA, VERA | 1653 | §102§112 | Non-Final OA | 4d overdue | Pending | Feb 29, 2024 |
| 18577623 | MODULAR PRIME EDITING SYSTEMS FOR GENOME ENGINEERING | UNIVERSITY OF MASSACHUSETTS | WARD, AARON DUREL | §102§112 | Non-Final OA | — | Pending | Jan 08, 2024 | |
| 18520821 | CONTROLLING PRESSURE | Emulate, Inc. | SINES, BRIAN J | 1796 | §103 | Non-Final OA | 55d | Pending | Nov 28, 2023 |
| 18497519 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITUS | Lyra Therapeutics, Inc. | GHERBI, SUZETTE JAIME J | 3774 | §102§103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | AmberGen, Inc. | PUTTLITZ, KARL J | §103§112DP | Non-Final OA | — | Pending | Oct 26, 2023 | |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | UNIVERSITY OF MASSACHUSETTS | KONOPKA, CATHERINE ANNE | 1635 | §101§102§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18027834 | CONTINUOUS INFRARED SPECTROSCOPY SYSTEM AND METHOD | Dxcover Limited | KIDWELL, KAITLYN ELIZABETH | 2877 | §102§103§112 | Final Rejection | 2d overdue | Pending | Mar 22, 2023 |
| 17921027 | IMPROVED CAS 12A/NLS MEDIATED THERAPEUTIC GENE EDITING PLATFORMS | UNIVERSITY OF MASSACHUSETTS | KONOPKA, CATHERINE ANNE | 1635 | §103 | Non-Final OA | 16d overdue | Pending | Oct 24, 2022 |
| 17639428 | DISCERNING BRAIN CANCER TYPE | Dxcover Limited | MACFARLANE, STACEY NEE | 1675 | §101§112 | Non-Final OA | 11d overdue | Pending | Mar 01, 2022 |
| 17608684 | CONVERSION OF CARBONATE INTO SYNGAS OR C2+ PRODUCTS IN ELECTROLYSIS CELL | The Governing Council of the University of Toronto | PARENT, ALEXANDER RENE | 1700 | §102§103§112 | Non-Final OA | — | Pending | Nov 03, 2021 |
| 16719103 | Inhibition Of TCR Signaling With Peptide Variants | Signablok, Inc. | LEE, JIA-HAI | 1658 | §112 | Non-Final OA | — | AI Ready | Dec 18, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial